Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318200 | 1.00 | SLC2A1 (0.42) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL150778 | 1.00 | SLC2A1 (0.42) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL1116562 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL1116558 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL4747690 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL8201748 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL3653142 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL8003273 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL1116556 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL22121795 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099480-B2 | MICROORGANISMS OF FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES | TE BIOS CO LTD (KR) | 2024-06-12 | — | — | EP | disclosed |
| US-20230235076-A1 | HUMANIZED ANTIBODIES AGAINST LEWIS Y | PENTIXAPHARM AG (DE) | 2023-07-27 | — | — | US | disclosed |
| EP-2099480-B1 | MICROORGANISMS OF FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES | GLYCOTOPE GMBH (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-9783599-B2 | LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same | PATRYS LIMITED (AU) | 2017-10-10 | — | — | US | disclosed |
| US-9494587-B2 | Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates | GLYCOTOPE GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| EP-2303924-B1 | LM-ANTIBODIES, FUNCTIONAL FRAGMENTS, LM-1 TARGET ANTIGEN, AND METHODS FOR MAKING AND USING SAME | PATRYS LTD (AU) | 2016-07-27 | — | — | EP | disclosed |
| CN-101573138-B | Microorganism and components that can activate cell immunity against carbohydrates | GLYCOTOPE GMBH | 2015-04-29 | — | — | CN | disclosed |
| US-20150071931-A1 | LM-Antibodies, Functional Fragments, LM-1 Target Antigen, and Methods for Making and Using Same | PATRYS LIMITED (AU) | 2015-03-12 | — | — | US | disclosed |
| EP-1920781-B1 | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors | GLYCOTOPE GMBH (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-20130101588-A1 | NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS | PATRYS LIMITED (AU) | 2013-04-25 | — | — | US | disclosed |
| US-20080199475-A1 | NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS | PATRYS LIMITED (AU) | 2008-08-21 | — | — | US | disclosed |
| US-20080139485-A1 | Methods and Compositions For Treating Diseases and Disorders Associated With Siglec-8 Expressing Cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008055703-A2 | MICROORGANISMS OR FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES | GLYCOTOPE GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1920781-A1 | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors | GLYCOTOPE GMBH (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-6235720-B1 | DRUG; MICROBIOCIDE, VIRICIDE, BACTERICIDE, ANTIPROTOZOA AGENT | GELTEX PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| US-5939537-A | Acid-functionalized saccharide monomers | GELTEX PHARMACEUTICALS INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5869460-A | ANTIINFLAMMATORY AGENTS | SANWA KAGUKU KENKYUSHO CO., LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| US-5821312-A | Acid-functionalized saccharides as polyvalent anti-infectives | GELTEX PHARMACEUTICALS, INC. (US) | 1998-10-13 | — | — | US | disclosed |
| US-5700458-A | Acid-functionalized saccharides as polyvalent anti-infectives | GELTEX PHARMACEUTICALS INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0771815-A1 | Sulfated and phosphated saccharide derivatives, process for the preparation of the same and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139485-A1 | Methods and Compositions For Treating Diseases and Disorders Associated With Siglec-8 Expressing Cells | SIGLEC7, SIGLEC9, FUT8 | SLC2A1 771/4885LGALS3 56/4885CA2 879/4885 |
| US-20230235076-A1 | HUMANIZED ANTIBODIES AGAINST LEWIS Y | FCGR2A, FCGR3B, CD47 | SLC2A1 797/4885LGALS3 27/4885CA2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.